|Heartwatch: a secondary prevention programme in primary care in Ireland.|
|PMID: 19177599 Owner: NLM Status: MEDLINE|
|BACKGROUND: Heartwatch, a secondary prevention programme in primary care was initiated in 2003, based on the second European Joint Task Force recommendations for secondary prevention of coronary heart disease (CHD). The aim was to examine the effect of the first 2 years of the Heartwatch programme on cardiovascular risk factors and treatments. DESIGN: Prospective cohort study of patients with established CHD enrolled into the Heartwatch programme. METHODS: Four hundred and seventy (20%) general practitioners nationwide participated in the programme, recruiting 11,542 patients with established CHD (earlier myocardial infarction, coronary intervention or coronary artery bypass surgery). Clinical data were electronically transferred by each general practitioner to a central database. Comparison of changes in risk factors and treatments at 1-year and 2-year follow-up from baseline were made using paired t-test for continuous and McNemar's test for categorical data. RESULTS: Statistically significant changes in systolic blood pressure, diastolic blood pressure, total and low-density lipoprotien cholesterol and smoking status at 1 and 2 years (P <0.0001) were observed. Little or no improvements were shown for exercise, BMI or waist circumference. Increases in the prescribing of statins, angiotensin-converting enzyme inhibitors and beta-blockers over the course of the study were observed. CONCLUSION: The Heartwatch programme has demonstrated significant improvements in the main risk factors and treatments for CHD. More effective interventions are required to reduce BMI, waist circumference and physical inactivity in this population. The increases in treatment uptake are approaching the optimal levels in this population.|
|Kathleen Bennett; Siobhan Jennings; Claire Collins; Michael Boland; John Leahy; Declan Bedford; Emer Shelley|
Related Documents :
|7079799 - The relation between stress and myocardial infarction: a general analysis.
688779 - Hemodynamic effects of smoking cigarettes of high and low nicotine content.
16762079 - Modular prevention of heart disease following acute coronary syndrome (acs) [isrctn4298...
17845879 - Perspectives that lay persons with and without health problems show toward coronary hea...
22861049 - Ventricular septal defect in a ferret (mustela putorius furo).
11791149 - Myocardial infarction and coronary pathology in severely obese people examined at autopsy.
2146309 - Coronary hemodynamic effects of atrial natriuretic peptide in humans.
8934009 - Techniques of management of subglottic stenoses with glottic and supraglottic problems.
2415079 - Further studies on the antiarrhythmic effect of iloprost.
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology Volume: 15 ISSN: 1741-8275 ISO Abbreviation: Eur J Cardiovasc Prev Rehabil Publication Date: 2008 Dec|
|Created Date: 2009-01-27 Completed Date: 2009-04-20 Revised Date: -|
Medline Journal Info:
|Nlm Unique ID: 101192000 Medline TA: Eur J Cardiovasc Prev Rehabil Country: England|
|Languages: eng Pagination: 651-6 Citation Subset: IM|
|Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Cardiovascular Agents / therapeutic use*
Coronary Disease / etiology, prevention & control*
Databases as Topic
Diabetes Complications / etiology, prevention & control
Dyslipidemias / complications, drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypertension / complications, drug therapy
Hypoglycemic Agents / therapeutic use
Medical Records Systems, Computerized
Obesity / complications, therapy
Primary Health Care*
Smoking / adverse effects, prevention & control
|0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Cardiovascular Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Hypoglycemic Agents|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Detection of novel biomarkers of liver cirrhosis by proteomic analysis.
Next Document: Regulation of biofilm formation in Escherichia coli K12: effect of mutations in HNS, StpA, lon, and ...